Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Actavis buys Warner Chilcott for $8.1bn

Executive Summary

Specialty pharmaco Actavis Inc. has acquired publicly traded Warner Chilcott PLC (generics) in a stock swap valued at $8.1bn, including the assumption of $3.4bn of debt. The combined company is expected to adopt the name Actavis PLC and will be led by the current Actavis team. WC shareholders will get 0.160 shares of Actavis (equal to $18.62, a 7% premium) for each share they own; WC investors will hold 23% of the new company, which will be located in Ireland and is expected to trade on the NYSE.
Deal Industry
  • Pharmaceuticals
    • Drug Delivery
      • Topical Delivery
    • Generic Drugs
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Payment Includes Stock
    • Includes Contract

Related Companies

Advertisement
UsernamePublicRestriction

Register